炎症性肠病患者SARS-CoV-2 mRNA疫苗免疫原性纵向研究:抗TNF治疗与年龄的影响
这项单中心前瞻性队列研究追踪了53例炎症性肠病(IBD)患者接种SARS-CoV-2 mRNA疫苗后12个月的体液和细胞免疫应答。结果显示,所有患者在3个月时均血清阳转,但抗TNF治疗与更快的抗体衰减显著相关,年龄增长也与中和抗体水平降低相关,而细胞免疫应答在不同治疗组间未见差异。
要点
- 抗TNF治疗与IBD患者接种mRNA疫苗后体液免疫应答更快衰减显著相关。
- 年龄每增加1岁,野生型中和抗体NT50降低2.4%。
- 细胞免疫应答(IFN-γ ELISpot)在抗TNF治疗组与其他治疗组间无显著差异。
核心结论
- 抗TNF治疗和较高年龄与IBD患者接种SARS-CoV-2 mRNA疫苗后较低且较短久的体液免疫应答相关。
- 细胞免疫应答在不同治疗组间似乎相对保留。
研究设计与样本
- 单中心前瞻性队列研究,纳入53例接受mRNA疫苗的成人IBD患者,分别在第3、6、12个月检测S1-RBD IgG、活病毒中和抗体滴度(NT50)和IFN-γ ELISpot。
主要发现
- 所有53例完成两剂接种且无感染史的患者在3个月时均血清阳转。
- S1-RBD IgG几何均值在3个月达峰(465.7 BAU/ml),6个月降至124.8 BAU/ml。
- 3个月时,针对Omicron BA.1的NT50几何均值(9.0)低于野生型(24.2)和Delta(26.9),13例(24.5%)从未达到野生型NT50 1:16。
- 抗TNF治疗(32/53,60.4%)与更快的抗体衰减显著相关;6个月时,调整后S1-RBD IgG几何均值比为0.31(95% CI 0.20-0.49),野生型NT50为0.22(95% CI 0.12-0.41)。
- 年龄每增加1岁,野生型NT50降低2.4%(比值0.976,95% CI 0.962-0.990)。
关键数值与推荐
- 在33例完成三剂接种的患者中,发生突破性感染(15/33)使S1-RBD IgG升高的幅度是仅接种第三剂的4.6倍,但中和抗体未见可测量的增益。
- 调整模型中,IFN-γ ELISpot应答在不同治疗组间无差异。
临床怎么用
- 对于接受抗TNF治疗的IBD患者,应关注其接种mRNA疫苗后体液免疫应答较弱且衰减较快。
- 老年IBD患者接种后中和抗体水平可能更低,需考虑加强免疫策略。
- 细胞免疫应答相对保留,可能对重症保护仍有意义。
局限性
- 探索性关联需在更大队列中验证,并需临床终点。
- 单中心研究,样本量较小(53例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with inflammatory bowel disease (IBD) on immunomodulatory therapy may respond less well to vaccination. We followed humoral and cellular responses to SARS-CoV-2 vaccination over 12 months. METHODS: In this single-centre, prospective cohort study, adults with IBD received mRNA vaccine under the Austrian national programme. Two doses were administered 28 days apart and a third dose 6-12 months after the first. S1-RBD IgG, live-virus 50% neutralisation titres (NT50) against wild-type, Delta, Omicron BA.1 and BA.2, and IFN-γ ELISpot responses were measured at baseline and after 3, 6 and 12 months. Associations with anti-TNF therapy and age were analysed with rank-based longitudinal models and with mixed-effects models adjusted for age and sex. RESULTS: All 53 twice-vaccinated, infection-naive patients seroconverted at 3 months. Geometric mean (GM) S1-RBD IgG peaked at 3 months (465.7 BAU/ml) and fell by 6 months (124.8 BAU/ml). At 3 months, GM NT50 values were lower against BA.1 (9.0) than against wild-type (24.2) or Delta (26.9), and 13 patients (24.5%) never reached a wild-type NT50 of 1:16. Anti-TNF therapy (32/53, 60.4%) was significantly associated with faster waning. At 6 months, adjusted geometric mean ratio versus other therapy was 0.31 (95% CI 0.20-0.49) for S1-RBD IgG and 0.22 (0.12-0.41) for wild-type NT50. Each additional year of age was associated with 2.4% lower wild-type NT50 (0.976 per year, 95% CI 0.962-0.990). In 33 thrice-vaccinated patients, intercurrent infection (15/33) raised S1-RBD IgG 4.6-fold more than the third dose alone, without a measurable gain in neutralisation. In the adjusted model, IFN-γ ELISpot responses did not differ between treatment groups. DISCUSSION: Anti-TNF therapy and higher age within a relatively young cohort were associated with lower and shorter-lived humoral responses, while cellular responses appeared comparatively preserved. These exploratory associations need confirmation in larger cohorts with clinical endpoints.
引用
- Mayr W, Knell AI, Boehm AK, et al. Longitudinal SARS-CoV-2 mRNA vaccine immunogenicity in inflammatory bowel disease in relation to anti-TNF therapy and age: a prospective cohort study. Vaccine. 2026. PMID: 42849224. doi:10.1016/j.vaccine.2026.129224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。